This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	EPH receptor B1 (EPHB1)	Rat studies suggest inhibiting EPHB1 signaling could help treat bone cancer pain and prevent morphine tolerance. In a rat model of bone cancer pain, spinal delivery of an Ephb1-blocking reagent prevented and reversed bone cancer pain and decreased tumor growth-associated bone destruction compared with delivery of a control reagent. In the same model, morphine plus an Ephb1-blocking reagent had a significant analgesic effect without development of tolerance compared with morphine alone. Next steps include pharmacological and toxicological studies of the blocking reagent in animals. SciBX 4(21); doi:10.1038/scibx.2011.603 Published online May 26, 2011	Unpatented; available for licensing from Parker University Contact: Jesse Green, Parker University, Dallas, Texas phone: 214-902-3487 e-mail: jgreen@parkercc.edu	Liu, S. <i>et al. Cancer Res.</i>; published online May 9, 2011; doi:10.1158/0008-5472.CAN-10-3870 Contact: Xue-Jun Song, Parker Research Institute, Dallas, Texas e-mail: song@parkercc.edu